Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of LTG-321 in Healthy Participants
NCT07110610Phase 1Completed
- Sponsor
- Latigo Biotherapeutics
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing LTG-321 with Placebo (2 arms). Primary endpoints: Incidence, severity, seriousness, and causality of treatment-emergent adverse events at 14 days, Pain Detection and Tolerance Threshold during Cold Pressor Test at 5 days and 1 more. Started Sep 2025; status: completed.
02
Drugs
LTG-321
03
Conditions
pain
Beyond the preview
Go deeper on NCT07110610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110610.